Essential Concepts in Molecular Pathology, Second Edition, offers an introduction to molecular genetics and the "molecular" aspects of human disease. The book illustrates how pathologists harness their understanding of these entities to develop new diagnostics and treatments for various human diseases. This new edition offers pathology, genetics residents, and molecular pathology fellows an advanced understanding of the molecular mechanisms of disease that goes beyond what they learned in medical and graduate school.
By bridging molecular concepts of pathogenesis to the clinical expression of disease in cell, tissue and organ, this fully updated, introductory reference provides the background necessary for an understanding of today's advances in pathology and medicine.
- Explains the practice of "molecular medicine" and the translational aspects of molecular pathology, including molecular diagnostics, molecular assessment and personalized medicine
- Orients non-pathologists on what pathologists look for and how they interpret their observational findings based on histopathology
- Provides the reader with what is missing from most targeted introductions to pathology-the cell biology behind pathophysiology
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
PART I Essential Pathology
Mechanisms of Disease 1. Molecular Mechanisms of Cell Death 2. Acute and Chronic Inflammation 3. Infection and Host Response 4. Neoplasia
PART II Concepts in Molecular Biology and Genetics 5. Basic Concepts in Human Molecular Genetics 6. The Human Genome: Implications for the Understanding of Human Disease 7. The Human Transcriptome: Implications for the Understanding of Human Disease 8. The Human Epigenome: Implications for the Understanding of Human Disease 9. Clinical Proteomics and Molecular Pathology 10. Integrative Systems Biology: Implications for the Understanding of Human Disease 11. Pathology: The Clinical Description of Human Disease 12. Molecular Pathogenesis: The Biological Basis of Human Disease and Implications for Improved Treatment of Human Disease 13. Integration of Molecular and Cellular Pathogenesis
PART IV Molecular Pathology of Human Disease 14. Molecular Basis of Cardiovascular Disease 15. Molecular Basis of Hemostatic and Thrombotic Diseases 16. Molecular Basis of Lymphoid and Myeloid Diseases 17. Molecular Basis of Diseases of Immunity 18. Molecular Basis of Pulmonary Disease 19. Molecular Basis of Diseases of the Gastrointestinal Tract 20. Molecular Basis of Liver Disease 21. Molecular Basis of Diseases of the Exocrine Pancreas 22. Molecular Basis of Diseases of the Endocrine System 23. Molecular Basis of Gynecologic Diseases 24. Molecular Pathogenesis of Kidney Diseases 25. Molecular Pathogenesis of Prostate Cancer: Somatic, Epigenetic, and Genetic Alterations 26. Molecular Biology of Breast Cancer 27. Molecular Basis of Skin Disease 28. Molecular Pathology: Neuropathology
PART V Practice of Molecular Medicine 29. Molecular Diagnosis of Human Disease 30. Molecular Assessment of Human Disease in the Clinical Laboratory 31. Pharmacogenomics and Personalized Medicine in the Treatment of Human Disease
William B. Coleman, PhD is the Executive Officer for the American Society for Investigative Pathology (Rockville, MD). Prior to taking this position with the American Society for Investigative Pathology, Dr. Coleman spent 28 years at the University of North Carolina School of Medicine (Chapel Hill, NC), first as a postdoctoral fellow (1990-1995) and then as a faculty member (1995-2018) in the Department of Pathology and Laboratory Medicine. During his time at the UNC School of Medicine, Dr. Coleman served as Director of Graduate Studies for the Molecular and Cellular Pathology Ph.D. Program (2006-2012; now the Pathobiology and Translational Medicine Ph.D. Program), was a co-founder of the UNC Program in Translational Medicine and served as its Co-Director (2006-2015) and then its Director (2015-2018), was affiliated with the Curriculum in Toxicology, the Cancer Biology Training Program, and was a member of the UNC Lineberger Comprehensive Cancer Center. Dr. Coleman was active in teaching biomedical graduate students and is a four-time recipient of the Joe W. Grisham Award for Excellence in Graduate Student Teaching from the Molecular and Cellular Pathology graduate students at the UNC School of Medicine. Prior to becoming an employee, Dr. Coleman was active in the leadership of the American Society for Investigative Pathology, serving in various roles including President (2015-2016). Dr. Coleman was honored with the ASIP Outstanding Investigator Award in 2013 from the American Society for Investigative Pathology. He is also a long-time member of the American Association for Cancer Research. He serves as Senior Associate Editor for The American Journal of Pathology, and is an Associate Editor for BMC Cancer, and PLoS One, and serves on the editorial boards of Clinica Chimica Acta, Experimental and Molecular Pathology, Archives of Pathology and Laboratory Medicine, Laboratory Investigation, and Current Pathobiology Reports, and has served as an ad hoc reviewer for 99 other journals. Dr. Coleman's major research interests are in the molecular pathogenesis of human cancers, with a specific interest in breast cancer epigenetics, liver carcinogenesis, and lung cancer biology. His research was funded by the NIH/NCI, The Susan G. Komen Breast Cancer Foundation, Friends for an Earlier Breast Cancer Test, and the UNC Lineberger Comprehensive Cancer Center. Dr. Coleman is the author of over 140 original research articles, reviews, and book chapters. In addition, Dr. Coleman has co-edited or co-authored ten books on topics related to molecular pathology, molecular diagnostics, and the molecular pathogenesis of human cancer.
Tsongalis, Gregory J.
Gregory Tsongalis, Ph.D., H.C.L.D., is the Vice Chair for Research and the Director of the Laboratory for Clinical Genomics and Advanced Technology (CGAT) in the Department of Pathology and Laboratory Medicine at the Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center (NCCC) in Lebanon, NH. He is a Professor of Pathology and Laboratory Medicine at the Audrey and Theodor Geisel School of Medicine at Dartmouth in Hanover, NH and a member of the NCCC Molecular Therapeutics Program and the gastrointestinal and breast cancer clinical oncology groups. In 2016 he became a member of Dartmouth College's Program in Experimental and Molecular Medicine (PEMM), and he has served on the advisory board of the Health Care Genetics Professional Science Master's Degree Program and Diagnostic Genetic Sciences Program at the University of Connecticut (Storrs, CT). His area of expertise is in the development and implementation of clinical molecular diagnostic technologies. His research interests are in the pathogenesis of human cancers, personalized medicine and disruptive technologies. He has authored/edited twelve textbooks in the field of molecular pathology, published more than 230 peer reviewed manuscripts, and has been an invited speaker at both national and international meetings. He has served on numerous committees of the American Association for Clinical Chemistry, the American Society for Investigative Pathology, the Federation for American Societies for Experimental Biology, and the Association for Molecular Pathology (where he is a past President). He is active in the Alliance for Clinical Trials in Oncology, the Association for Molecular Pathology, the American Association for Clinical Chemistry, the American Association of Bioanalysts, and the American Society for Investigative Pathology. He serves on the editorial boards of 8 journals including Clinical Chemistry, Experimental and Molecular Pathology, and the Journal of Molecular Diagnostics. In 2016, Dr. Tsongalis received the Norris Cotton Cancer Center Award for Excellence, in 2017 the Association for Molecular Pathology (AMP) Jeffrey A. Kant Leadership Award, and in 2019 the American Society for Investigative Pathology Robbins Distinguished Educator Award. He also serves on numerous corporate scientific advisory boards.